Table 1.

Conclusions and recommendations for the implementation of P3PT based on community feedback analysis

Area	Conclusion/recommendation	Benefit
P3PT implementation	Careful and stepwise implementation recommended	Widespread acceptance more likely
	Initial preclinical multicenter studies should be performed by experienced centers, ideally having a long-standing history of collaboration	Swift and exact estimation of P3PT benefit under practical conditions
P3PT organization and governance	Centralized study governance and central study protocol	Clinical-trial like design, enhanced result comparability
	Core endpoints addressed by all centers according to P3PT protocol	Enhanced statistical power and higher predictability for primary endpoints
	Additional: individual endpoints addressed by single centers with outstanding competencies	Broad spectrum of translationally endpoints addressable (but no benefit for study power)
P3PT animal models	Use of multiple models, if applicable	Better representation of patient population (polypharmacy, age, sex, comorbidities)
	Use of large animal models, if available	Reflecting gyrencephalic brain structure, closer similarity to human situation
P3PT quality assurance	Further enhancing awareness for those (might require institutional support [9])	Increasing scientific rigor and result comparability, reducing divergences in relevance acknowledgment throughout the community
	Strict application of quality assurance criteria	Enhanced result comparability and relevance
P3PT financing and result publication	Establishing and recruiting of global funds	International and -continental collaboration facilitated, reduced financial burden for national public funding authorities
	Early enrolment of high-quality academic-industry collaborations	Timely involvement of key stakeholders, preventing failure of clinical trials, bolstering financial resources for P3PT
	Establishing centralized writing committees	More efficient workflow, comparability to large scale clinical trials